SUBSCRIBERS
How Gilead arrived at US$1,000 a pill price
What sets pricing is not R&D costs but potential insurer reaction and the chance to set a price benchmark: report
Add BT as a preferred sourcePublished Fri, Dec 11, 2015 · 09:50 PM
New York
FROM the start, the miracle drug was expected to carry a high price tag: US$36,000 to treat each patient.
Over the two years leading up to the medicine's 2013 launch, Gilead Sciences Inc executives and advisers inched the number higher, to about US$65,000, then to US$81,000, then to US$84,000 - or US$1,000 a pill for the 12-week treatment - as they homed in on a price that was just below where they thought insurers would add restrictions for the breakthrough hepatitis C remedy.
Share with us your feedback on BT's products and services
